A new, computerized, mental health assessment tool may allow doctors to quickly identify children experiencing anxiety or ...

There are several tests that doctors can use to diagnose and monitor COPD. Let's take a look at what abnormal values for ...

Thus, at present, the MRC dyspnea scale appears to be an appropriate tool to stratify COPD in the ED ... It should include an assessment of mental status, tracheal position and tug, use of ...

This is utilizing NHS resources that could be allocated to another priority area if these people are provided with the tools to self ... NICE early value assessment will evaluate innovative digital ...

“With COPD, a lot of common viruses—things like respiratory ... With the help of advanced genetic testing, blood analyses, and other cutting-edge assessment tools, doctors can get a clearer picture of ...

After 12 weeks of nebulized NAC, patients’ mean phlegm scores, as measured by the COPD assessment test, significantly decreased from 3.47 at baseline to 2.62. N-acetylcysteine (NAC) nebulizer ...

A project to pick up undiagnosed COPD in people who had attended lung health checks found 70% of those offered an assessment had the condition. Those involved in the scheme said the findings suggest ...

Oct. 2, 2024 — The FDA has approved Regeneron and Sanofi’s drug Dupixent for patients with COPD (chronic obstructive pulmonary disease). Marking the sixth indication for the drug, the approval ...

The drug was cleared for use in adults whose COPD symptoms aren’t under control and whose disease is driven by eosinophils, a type of immune cell that can contribute to inflammation. There are ...

The FDA has granted a supplementary approval to Regeneron and Sanofi’s dupilumab (Dupixent) for use as an add-on therapy for inadequately controlled chronic obstructive pulmonary disease (COPD ...

This approval was based on results from the phase 3 BOREAS (NCT03930732) and NOTUS (NCT04456673) trials, which demonstrated that dupilumab can significantly reduce COPD exacerbations. 2 The first ...

More than 220 patients with AATD were recruited to the study alongside patients with COPD and a control nonlung disease population, and all were assessed for present cardiovascular disease (CVD) and ...